Skip to Content

Join the 'Non-Hodgkin's Lymphoma' group to help and get support from people like you.

Non-Hodgkin's Lymphoma News

Related terms: Cancer, Non-Hodgkin's Lymphoma, Histiocytic Lymphoma, Lymphoblastic Lymphoma, Lymphocytic Lymphoma, Lymphoma, Histiocytic, Lymphoma, Lymphoblastic, Lymphoma, Lymphocytic, Lymphoma, Non-Hodgkin's

Get Active, Beat Lymphoma?

Posted 5 days ago by Drugs.com

TUESDAY, Dec. 12, 2017 – Physical activity appears to help people with lymphoma survive their disease. That finding comes from a new study by Mayo Clinic researchers of nearly 4,100 people with lymphoma, a cancer that starts in the white blood cells that normally help fight infection. "As physicians, we recommend physical activity for all cancer survivors to improve overall quality of life, but we did not know if physical activity would have an impact on survival in lymphoma patients," said study author Dr. Priyanka Pophali, a hematologist at Mayo Clinic. "Our findings show that physical activity can have a positive impact on survival in lymphoma patients," she said in a Mayo news release. Through periodic questionnaires, the researchers tracked the participants' physical activity levels from before their cancer diagnoses until three years afterwards. People whose physical activity was ... Read more

Related support groups: Lymphoma, Non-Hodgkin's Lymphoma, Follicular Lymphoma, Hodgkin's Lymphoma, Burkitt Lymphoma, Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma

FDA Approves 2nd Gene Therapy Yescarta

Posted 19 Oct 2017 by Drugs.com

THURSDAY, Oct. 19, 2017 – The U.S. Food and Drug Administration has approved the second gene therapy for use in the United States. The new treatment, Yescarta (axicabtagene ciloleucel), is for a kind of blood cancer called large B-cell lymphoma. The treatment is known as chimeric antigen receptor (CAR) T cell therapy, and is only the second such therapy sanctioned by the FDA. In August, the agency approved a similar CAR-T cell therapy to help battle a childhood leukemia. The FDA's move on Wednesday helps open a new phase in medical care, where genetics are used to help further treatment. "Today marks another milestone in the development of a whole new scientific paradigm for the treatment of serious diseases," FDA Commissioner Dr. Scott Gottlieb said in the news release. "In just several decades, gene therapy has gone from being a promising concept to a practical solution to deadly and ... Read more

Related support groups: Non-Hodgkin's Lymphoma, Yescarta, Diffuse Large B-Cell Lymphoma, Axicabtagene Ciloleucel

Gene Therapy, Yescarta (axicabtagene ciloleucel), Approved for B-Cell Lymphoma

Posted 19 Oct 2017 by Drugs.com

THURSDAY, Oct. 19, 2017 --Yescarta (axicabtagene ciloleucel) has been approved by the U.S. Food and Drug Administration as the first form of gene therapy for a non-Hodgkin lymphoma (NHL) form of cancer. Diffuse large B-cell lymphoma is the most common form of this immune system cancer in adults, the agency said in a news release. Some 72,000 cases of NHL are diagnosed each year in the United States, and the Diffuse large-B cell form represents about a third of these cases, the FDA added. This is only the second form of gene therapy approved by the FDA. The technique uses cells from the patient's own immune system to create a custom treatment to help fight the cancer. In this case, the patient's white blood cells called T-cells are modified to include a new gene that targets and kills lymphoma cells, then re-infused back into the patient. "In just several decades, gene therapy has gone ... Read more

Related support groups: Non-Hodgkin's Lymphoma, Yescarta, Diffuse Large B-Cell Lymphoma, Axicabtagene Ciloleucel

FDA Approves Yescarta (axicabtagene ciloleucel) CAR-T Cell Therapy to Treat Adults with Certain Types of Large B-Cell Lymphoma

Posted 19 Oct 2017 by Drugs.com

October 18, 2017 – The U.S. Food and Drug Administration today approved Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment. Yescarta, a chimeric antigen receptor (CAR) T cell therapy, is the second gene therapy approved by the FDA and the first for certain types of non-Hodgkin lymphoma (NHL). “Today marks another milestone in the development of a whole new scientific paradigm for the treatment of serious diseases. In just several decades, gene therapy has gone from being a promising concept to a practical solution to deadly and largely untreatable forms of cancer,” said FDA Commissioner Scott Gottlieb, M.D. “This approval demonstrates the continued momentum of this promising new area of medicine and we’re committed to ... Read more

Related support groups: Lymphoma, Non-Hodgkin's Lymphoma, Yescarta, Diffuse Large B-Cell Lymphoma, Axicabtagene Ciloleucel

Childhood Cancer Survivors Now Living Healthier Lives

Posted 2 Jun 2017 by Drugs.com

FRIDAY, June 2, 2017 – For people who battled cancer in childhood, the prospects for a long life without cancer recurrence or chronic illness are better than ever, a new study finds. That's largely due to changes in cancer treatment protocols that have meant less toxicity to children and less chance for long-term side effects, researchers said. This is the first "comprehensive" study on the issue, said study author Dr. Todd Gibson, who's with the cancer control department at St. Jude Children's Research Hospital in Memphis, Tenn. As the researchers explained, more children are surviving cancer, but the chemotherapy and radiation they receive as treatment can raise their risk for adult illness years later. So, cancer specialists have worked hard over time to modify treatments to maximize benefits but minimize long-term risks. And it seems to have paid off. In the new study, Gibson's ... Read more

Related support groups: Cancer, Leukemia, Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia, Hodgkin's Lymphoma, Wilms' Tumor, History - Radiation Therapy

Cancer Risk Rises After Childhood Organ Transplant: Study

Posted 26 Apr 2017 by Drugs.com

WEDNESDAY, April 26, 2017 – Children given an organ transplant have a substantially higher risk of developing cancer – in some cases up to 200 times higher – than the general population, a new study finds. But the individual risk of any one child getting cancer still remains very small, the study authors stressed. Overall, the U.S. National Cancer Institute (NCI) study found that the risk for cancer among children who received transplants was 19 times higher than in the general population. Non-Hodgkin's lymphoma was the cancer with a 200 times higher risk. Seventy-one percent of those who developed cancer after a pediatric organ transplant had non-Hodgkin's lymphoma, the study findings showed. "We knew going into the study that the risk of lymphoma would be very high," explained Dr. Eric Engels, the study's senior investigator. "That's been seen in much smaller studies, and it's been ... Read more

Related support groups: Cancer, Leukemia, Renal Transplant, Non-Hodgkin's Lymphoma, Organ Transplant - Rejection Prophylaxis, Viral Infection, Organ Transplant, Kidney Transplant, Organ Transplant - Rejection Reversal, Rejection Reversal, Rejection Prophylaxis

Gene Therapy Shows Promise for Aggressive Lymphoma

Posted 28 Feb 2017 by Drugs.com

TUESDAY, Feb. 28, 2017 – An experimental gene therapy for aggressive non-Hodgkin lymphoma beat back more than a third of cancers that seemed untreatable, the therapy's developers report. Thirty-six percent of over 100 very ill lymphoma patients appeared disease-free six months after a single treatment, according to results released by the treatment's maker, Kite Pharma of Santa Monica, Calif. These patients had not responded to usual treatments and had no other options, Kite said Tuesday in a news release. Overall, more than four out of five patients with the blood cancer saw their cancer reduced by more than half for at least part of the study, the company said. "This seems extraordinary ... extremely encouraging," one cancer specialist, Dr. Roy Herbst, told the Associated Press. But Herbst, who is chief of medical oncology at Yale Cancer Center in New Haven, Conn., said longer ... Read more

Related support groups: Cancer, Lymphoma, Non-Hodgkin's Lymphoma

DNA Sequencing May Lead to Personalized Cancer Treatment

Posted 9 Nov 2016 by Drugs.com

WEDNESDAY, Nov. 9, 2016 – DNA sequencing may help personalize treatment for people with lymphoma, a new study suggests. By analyzing small bits of DNA in the blood, researchers at Stanford University School of Medicine said they could determine the cancer's subtype. They said they could also identify mutations that might make treatment less effective or worsen a patient's prognosis. The study authors said their findings add to growing evidence that noninvasive, blood-based biopsies may help detect cancer earlier by tracking its evolution. They said this test may also significantly change how the disease is treated. "Now we can identify the subtype of the tumor, watch how it changes over time and begin to tailor our chemotherapy choices based on the presence or absence of specific mutations," said study co-senior author Dr. Ash Alizadeh, an assistant professor of medicine/oncology. ... Read more

Related support groups: Cancer, Lymphoma, Non-Hodgkin's Lymphoma, Follicular Lymphoma, Hodgkin's Lymphoma, Cutaneous T-cell Lymphoma, Diagnosis and Investigation, Mantle Cell Lymphoma, Burkitt Lymphoma, Peripheral T-cell Lymphoma, Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma

Immune Therapy Makes Headway Against a Lymphoma

Posted 8 Sep 2016 by Drugs.com

THURSDAY, Sept. 8, 2016 – Genetically engineered immune cells appear capable of eradicating non-Hodgkin lymphoma when coupled with effective chemotherapy, a new early trial finds. In this experimental therapy, white blood cells known as T-cells are removed from the patient's bloodstream. Then they're genetically modified so they can detect and attack cancerous B-cells, another type of white blood cell in which most types of non-Hodgkin lymphoma occur. One-third of 32 patients treated with the modified T-cells experienced a complete remission of their non-Hodgkin lymphoma. And those pretreated with more aggressive chemotherapy did even better, researchers report. "It's a fantastic step forward," said Susanna Greer, director of clinical research and immunology at the American Cancer Society. "It's been difficult to make a lot of progress in lymphoma, especially in non-Hodgkin lymphoma, ... Read more

Related support groups: Non-Hodgkin's Lymphoma, Follicular Lymphoma, Cutaneous T-cell Lymphoma, Diagnosis and Investigation, Burkitt Lymphoma, Mantle Cell Lymphoma, Waldenström Macroglobulinemia, Mycosis Fungoides, Peripheral T-cell Lymphoma

Stem Cell Transplant Can Help HIV Patients Battling Lymphoma: Study

Posted 15 Jun 2016 by Drugs.com

WEDNESDAY, June 15, 2016 – People living with HIV are at high risk for lymphoma, and a new study concludes that stem cell transplant should be standard treatment in these cases. The transplants should be "autologous" – meaning the cells come from the patients themselves, the researchers said. The new findings could challenge the widely held belief that HIV-positive patients are not candidates for this therapy. Instead, the study found that "overall survival for patients with HIV infection after transplant is comparable to that seen in people who were not HIV-infected," said study lead author Dr. Joseph Alvarnas. As his team explained, people with HIV are at increased risk for cancer, even if their infection is well-controlled with antiretroviral drugs. In fact, cancer is now a leading cause of death among HIV patients. The risk of non-Hodgkin lymphoma, specifically in HIV-positive ... Read more

Related support groups: HIV Infection, Lymphoma, Non-Hodgkin's Lymphoma

FDA Medwatch Alert: BiCNU (carmustine for injection): FDA Alert - Counterfeit Product Discovered in Some Foreign Countries

Posted 16 May 2016 by Drugs.com

ISSUE: FDA is informing health care professionals that a counterfeit version of the FDA approved cancer drug, BiCNU (carmustine for injection) 100 mg, has been detected in some foreign countries. There is no indication at this time that counterfeit BiCNU has entered the legitimate U.S. drug supply chain and no indication that any U.S. patients have received counterfeit BiCNU. See the FDA Alert for more information, including product photos and affected lot numbers. BACKGROUND: The authentic product is approved to treat different types of brain cancer, multiple myeloma, and lymphoma (Hodgkin’s and non-Hodgkin’s). BiCNU is manufactured by Emcure Pharmaceuticals Ltd. and distributed in the United States by Heritage Pharmaceuticals Inc. BiCNU is available as a vial of BiCNU and dehydrated alcohol co-packaged together. While the NDC on the outer package of the authentic and counterfeit ver ... Read more

Related support groups: Brain Tumor, Multiple Myeloma, Non-Hodgkin's Lymphoma, Glioblastoma Multiforme, Hodgkin's Lymphoma, Malignant Glioma, BiCNU

FDA Alerts Healthcare Professionals About Clinical Trials with Zydelig (idelalisib) in Combination with other Cancer Medicines

Posted 16 Mar 2016 by Drugs.com

March 14, 2016 – The U.S. Food and Drug Administration is alerting health care professionals about reports of an increased rate of adverse events, including deaths, in clinical trials with the cancer medicine Zydelig (idelalisib) in combination with other cancer medicines. Gilead Sciences, Inc. has confirmed that they are stopping six clinical trials in patients with chronic lymphocytic leukemia, small lymphocytic lymphoma and indolent non-Hodgkin lymphomas. The FDA is reviewing the findings of the clinical trials and will communicate new information as necessary. Health care professionals should be aware that Zydelig is not approved for previously untreated chronic lymphocytic leukemia. Zydelig is currently approved by the FDA for the treatment of: Relapsed chronic lymphocytic leukemia, in combination with rituximab, in patients for whom rituximab alone would be considered ... Read more

Related support groups: Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma, Zydelig

Teva Pharmaceuticals and Eagle Pharmaceuticals Announce FDA Approval of Bendeka (bendamustine hydrochloride) Injection

Posted 10 Dec 2015 by Drugs.com

JERUSALEM & WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Dec. 8, 2015-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) today announce that the U.S. Food and Drug Administration (FDA) has approved Bendeka, (bendamustine hydrochloride) injection, a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine. Bendeka is approved for the treatment of patients with chronic lymphocytic leukemia (CLL) and for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Efficacy in CLL relative to first-line therapies other than chlorambucil has not been established. “We are thrilled that the FDA has approved Bendeka and are excited for what we believe will be a promising launch with Teva. Importantly, w ... Read more

Related support groups: Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma, Bendamustine, Bendeka

Young Cancer Survivors Often Develop New Malignancies

Posted 6 Oct 2015 by Drugs.com

TUESDAY, Oct. 6, 2015 – Teen and young adult cancer survivors are at increased risk for other cancers later in life, a new study reveals. Researchers analyzed U.S. National Cancer Institute data on people who survived cancers before age 40. They had the most common types of cancers in that age group: leukemia, lymphoma, testicular, ovarian, thyroid, breast, soft tissue and bone cancers. "This is a patient demographic that has been largely overlooked," said senior study author Dr. Robert Goldsby, a professor of pediatrics at the University of California, San Francisco Benioff Children's Hospital. Over 30 years, nearly 14 percent of the survivors were diagnosed with another, different type of cancer. On average, the second cancer occurred within 15 years. Compared to people in the general population, patients successfully treated for cancer between ages 15 and 39 were nearly 60 percent ... Read more

Related support groups: Cancer, Breast Cancer, Hairy Cell Leukemia, Leukemia, Chronic Myelogenous Leukemia (CML), Basal Cell Carcinoma, Lymphoma, Skin Cancer, Melanoma, Chronic Lymphocytic Leukemia (CLL), Ovarian Cancer, Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Stomach Cancer, Acute Lymphoblastic Leukemia, Hodgkin's Lymphoma, Cutaneous T-cell Lymphoma, Mantle Cell Lymphoma, Soft Tissue Sarcoma, Burkitt Lymphoma

Genetically Modified Foods, Herbicides and Human Safety

Posted 19 Aug 2015 by Drugs.com

WEDNESDAY, Aug. 19, 2015 – Farm fields are becoming soaked with increasing amounts of suspected cancer-causing herbicides, thanks to the spread of genetically modified crops that are immune to these chemicals, two researchers contend. They make their argument in a Perspective piece in the Aug. 20 issue of the New England Journal of Medicine. Farmers' use of glyphosate – a weedkiller most commonly known as Roundup – has increased by a factor of more than 250 in the United States, climbing from 0.4 million kilograms in 1974 to 113 million kilograms in 2014, the researchers said. This increase is due to crops such as corn and soybeans that have been genetically altered to be "Roundup-Ready," so they can't be affected by these herbicides, said one of the researchers, Charles Benbrook. He is a research professor at the Washington State University Center for Sustaining Agriculture and ... Read more

Related support groups: Cancer, Poisoning, Non-Hodgkin's Lymphoma, Toxic Reactions Incl Drug and Substance Abuse

Page 1 2 3 Next

Ask a Question

Further Information

Related Condition Support Groups

Mantle Cell Lymphoma, Follicular Lymphoma, Waldenström Macroglobulinemia, Cutaneous T-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma, Peripheral T-cell Lymphoma, Lymphoma

Related Drug Support Groups

methotrexate, Rituxan, rituximab, Imbruvica, Cytoxan, bendamustine, cyclophosphamide, Treanda, ibrutinib, view more... vincristine, cytarabine, Zevalin, Folotyn, Neosar, Oncovin, Bexxar, Methotrexate LPF Sodium, Fludara, bleomycin, Blenoxane, idelalisib, Cytosar, ibritumomab, Bendeka, Cytosar-U, Mozobil, Bexxar Dosimetric, BexxarTherapeutic, Oforta, Zydelig, Y-90 Zevalin, In-111 Zevalin, Novantrone, Tarabine PFS, pralatrexate, fludarabine, mitoxantrone, teniposide, tositumomab / iodine i 131 tositumomab, plerixafor, tositumomab, BiCNU, Folex PFS, Gliadel, Trexall, carmustine, Vumon, Vincasar PFS, Cytoxan Lyophilized, Bleo 15k